Phathom Pharmaceuticals, Inc. (PHAT) Cash Flow Statement
Phathom Pharmaceuticals, Inc. (PHAT) generated -$36.7M of operating cash flow over the twelve months to 2026-06-30, spent $219000 on capital expenditure and had free cash flow of -$36.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PHATPhathom Pharmaceuticals, Inc.Follow PHAT — free
—
Price chart with a free account
- Market cap
- 464.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -137.6 | -266.8 | -166.8 | -36.7 | |
| Capital expenditure | 1.6 | 0.1 | 0.2 | -0.2 | |
| Free cash flow | -139.2 | -266.9 | -167.0 | -36.9 | |
| Stock-based compensation | 45.0 | 24.0 | 28.7 | — |
USD millions · SEC XBRL
Phathom Pharmaceuticals, Inc. — questions
- What is Phathom Pharmaceuticals, Inc.'s operating cash flow?
- -$36.7M over the twelve months to 2026-06-30.
- How much does Phathom Pharmaceuticals, Inc. spend on capital expenditure?
- $219000 over the twelve months to 2026-06-30.
- What is Phathom Pharmaceuticals, Inc.'s free cash flow?
- -$36.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Phathom Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.